Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$58.85 USD
+0.06 (0.10%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $58.81 -0.04 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Exact Sciences (EXAS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$91.06 | $115.00 | $66.00 | 54.89% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Exact Sciences comes to $91.06. The forecasts range from a low of $66.00 to a high of $115.00. The average price target represents an increase of 54.89% from the last closing price of $58.79.
Analyst Price Targets (17)
Broker Rating
Exact Sciences currently has an average brokerage recommendation (ABR) of 1.32 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 19 brokerage firms. The current ABR compares to an ABR of 1.32 a month ago based on 19 recommendations.
Of the 19 recommendations deriving the current ABR, 16 are Strong Buy, representing 84.21% of all recommendations. A month ago, Strong Buy represented 84.21%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 16 | 16 | 16 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.32 | 1.32 | 1.32 | 1.32 | 1.32 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/12/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
3/1/2024 | Craig-Hallum | Alex Nowak | Strong Buy | Strong Buy |
2/27/2024 | BTIG | Mark Massaro | Strong Buy | Strong Buy |
2/22/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
2/22/2024 | Canaccord Genuity | Kyle Mikson | Strong Buy | Strong Buy |
1/29/2024 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
1/8/2024 | William Blair | Andrew F Brackmann | Strong Buy | Strong Buy |
1/2/2024 | The Benchmark Company | Bruce D Jackson | Hold | Hold |
12/14/2023 | Guggenheim Securities | Subbu Nambi | Not Available | Strong Buy |
11/2/2023 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.32 |
ABR (Last week) | 1.32 |
# of Recs in ABR | 19 |
Average Target Price | $91.06 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.50 |